Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/122618

In Collections

This item can be found in the following collections:

Mastellos, D.C.; Reis, E.S.; Biglarnia, A.R.; Waldman, M.; Quigg, R.J.; Huber-Lang, M.; ... ; Lambris, J.D. (2019)

Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?

Article / Letter to editor
Owing to an increasing shortage of donor organs, the majority of patients with end-stage kidney disease remains reliant on extracorporeal hemodialysis (HD) in order to counter the lifelong complications of a failing kidney. While HD remains a life-saving option for these patients, mounting evidence suggests that it also fuels a vicious cycle of thromboinflammation that can increase the risk of cardiovascular disease. During HD, blood-borne innate immune systems become inappropriately activated on the biomaterial surface, instigating proinflammatory reactions that can alter endothelial and vascular homeostasis. Complement activation, early during the HD process, has been shown to fuel a multitude of detrimental thromboinflammatory reactions that collectively contribute to patient morbidity. Here we discuss emerging aspects of complement's involvement in HD-induced inflammation and put forth the concept that targeted intervention at the level of C3 might constitute a promising...Show moreOwing to an increasing shortage of donor organs, the majority of patients with end-stage kidney disease remains reliant on extracorporeal hemodialysis (HD) in order to counter the lifelong complications of a failing kidney. While HD remains a life-saving option for these patients, mounting evidence suggests that it also fuels a vicious cycle of thromboinflammation that can increase the risk of cardiovascular disease. During HD, blood-borne innate immune systems become inappropriately activated on the biomaterial surface, instigating proinflammatory reactions that can alter endothelial and vascular homeostasis. Complement activation, early during the HD process, has been shown to fuel a multitude of detrimental thromboinflammatory reactions that collectively contribute to patient morbidity. Here we discuss emerging aspects of complement's involvement in HD-induced inflammation and put forth the concept that targeted intervention at the level of C3 might constitute a promising therapeutic approach in HD patients.Show less
Hemodialysis
Complement C3
Compstatins
Cp40
Thromboinflammation
AMY-101
All authors
Mastellos, D.C.; Reis, E.S.; Biglarnia, A.R.; Waldman, M.; Quigg, R.J.; Huber-Lang, M.; Seelen, M.A.; Daha, M.R.; Lambris, J.D.
Date
2019-01-01
Journal
Clinical Immunology
Volume
198
Pages
102 - 105
DOI
doi:10.1016/j.clim.2018.11.010